Month: <span>December 2019</span>

Pfizer Extends its Research and License Agreement with BioInvent to

Shots: Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones […]Read More

AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance

Shots: The approval follows PR designation and is based on P-III KRONOS study assessing budesonide/glycopyrronium/formoterol fumarate vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate, demonstrated significant improvement in FEV1 The approval marks the first NMPA approval for a fixed-dose triple-combination regimen in a pressurized metered-dose inhaler device which utilizes Aerosphere delivery technology Breztri Aerosphere […]Read More

Allergan’s Ubrelvy (ubrogepant) Receives the US FDA’s Approval for Acute

Shots: The US FDA’s approval is based on four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002), which demonstrated efficacy, safety and tolerability of Ubrelvy (50, 100mg) for the acute treatment of migraine with/-out aura in adults The studies resulted in meeting its 1EPs i.e, elimination in migraine pain and the most bothersome symptom […]Read More

Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in

Shots: Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in Japan for RA and other future indications Following the approval, the companies will jointly commercialize filgotinib. The agreement will extend to additional potential indications for […]Read More

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for

Shots: Theravance to receive $10M up front, up to $240M development & commercial milestones with royalties on global sales of any product developed from the program. Pfizer to get a global license for Theravance’s skin-targeted, LA, pan-Janus kinase (JAK) inhibitors   Pfizer will validate Theravance’s expertise in the discovery & development of organ-selective JAK inhibitors […]Read More

Johnson & Johnson to Acquire TARIS Biomedical for its Drug

Shots: J&J acquires TARIS Biomedical while TARIS to continue research in Lexington, Massachusetts and will also become part of Janssen R&D’s Oncology Therapeutic Area. Additionally, the companies will focus on optimization of drug candidates for advancing and delivering future clinical programs utilizing TARIS technology The focus of an acquisition is to utilize TARIS’ drug delivery […]Read More

Roche Signs an Exclusive Worldwide Option and License Agreement with

Shots: Rhoes to receive $42.5M up front, milestones $90M for specified research and preclinical development plus option fees, $660M milestones based on development, regulatory and sales plus royalties on sales. Roche to get exclusive option to license for defined no. of candidates while Rhoes will conduct research to discover and develop novel candidates in immunometabolism […]Read More